Richard Finn, MD

Richard S. Finn, MD, discusses how he sees the field of hepatocellular carcinoma evolving in the future.

Richard Finn, MD, from UCLA's Jonsson Comprehensive Cancer Center, discusses the difficulties of treating liver cancer.

Richard Finn, MD, from UCLA, discusses the treatment of patients with estrogen receptor-positive (ER+) breast cancer with antiestrogens.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, UCLA, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer.

Richard Finn, MD, comments on the future of palbociclib (PD 0332991), a novel oral selective inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), for the treatment of breast cancer.